Pharmafile Logo
Pharmafocus logo
Advanced Search

non small cell lung cancer

Showing 9 posts of 9 posts found.

European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer

April 4, 2019
Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …

News
Keytruda image

MSD’s Keytruda impresses in lung cancer chemotherapy trial

December 21, 2015
Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …

News
NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

News
MHRA

Early UK access for AstraZeneca lung cancer drug

December 9, 2015
AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib

UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …

News
lung cancer x ray

Lung cancer market to hit $10.9bn by 2021

September 10, 2015
Sales and Marketing AZD9291, GBI Research, GlobalData, NSCLC, industry analysis, industry intelligence, industry reports, keytruda, market intelligence lung cancer, market reports, market trends, non small cell lung cancer, non-small cell lung cancer, opdivo, world conference on lung cancer

The global market value for non-small cell lung cancer treatment will rise from $6.9 billion in 2014 to $10.9 billion …

News
Opdivo

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

August 12, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …

News
Lung cancer cells

No magic bullet, but a growing arsenal against lung cancer

February 23, 2011
Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer

A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …

Feature

Blood clot fears halt cancer trial enrolment

February 3, 2011
Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

News

Novartis drops late stage lung cancer candidate

November 11, 2010
Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer

Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …

News

Latest content

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023